PUBLISHER: The Business Research Company | PRODUCT CODE: 1945364
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945364
In vitro diagnostics (IVD) are tests performed on biological samples, such as blood, tissue, or urine, collected from the human body to identify diseases, conditions, or infections. Conducted outside the body in controlled environments like laboratories, these tests utilize specialized equipment and reagents. IVDs play a vital role in diagnosing various health conditions, guiding treatment decisions, and monitoring patient health over time.
The principal categories of in-vitro diagnostics equipment encompass point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices and equipment, and immunohematology diagnostic devices and equipment. Hematology instruments, for instance, are machines designed to analyze blood samples, perform blood counts, detect proteins or enzymes, and aid in the diagnosis of diseases or genetic defects. These devices and equipment are used in both public and private settings and involve instruments/equipment as well as disposables. The end-users for these tools include hospitals and clinics, diagnostic laboratories, and other relevant institutions.
Tariffs are influencing the in vitro diagnostics market by increasing costs of imported analyzers, reagents, microfluidic components, and optical systems used across diagnostic platforms. North America and Europe are most affected due to reliance on globally sourced diagnostic equipment, while Asia-Pacific faces higher costs for reagent imports and exports. These tariffs are raising testing costs and delaying laboratory upgrades. However, they are also encouraging domestic manufacturing, regional reagent production, and strengthened local diagnostic supply chains.
The in vitro diagnostics market research report is one of a series of new reports from The Business Research Company that provides in vitro diagnostics market statistics, including in vitro diagnostics industry global market size, regional shares, competitors with a in vitro diagnostics market share, detailed in vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro diagnostics industry. This in vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The in vitro diagnostics market size has grown rapidly in recent years. It will grow from $136.55 billion in 2025 to $152.42 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to expansion of diagnostic testing volumes, growth in infectious disease screening, rising burden of chronic diseases, improvements in laboratory infrastructure, increasing healthcare access.
The in vitro diagnostics market size is expected to see rapid growth in the next few years. It will grow to $241.14 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing adoption of decentralized diagnostics, rising investments in molecular testing technologies, expansion of personalized medicine diagnostics, growing demand for rapid and accurate testing, increasing integration of ai-driven diagnostics. Major trends in the forecast period include increasing adoption of point-of-care diagnostic devices, rising demand for molecular and immunoassay testing, growing use of automated laboratory systems, expansion of multiplex diagnostic platforms, enhanced focus on rapid testing.
The rising prevalence of cancer is expected to drive the growth of the in vitro diagnostics (IVD) market. Cancer encompasses over 100 different diseases that can develop in various parts of the body. The increasing incidence of cancer is largely attributed to lifestyle factors such as increased tobacco use, poor diet, physical inactivity, and environmental pollution, all of which elevate the risk of cancer across populations. In vitro diagnostics (IVDs) are a category of tests or medical devices that analyze samples taken from the human body, providing essential information for the screening, diagnosis, and treatment of cancer. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported that there were 1,958,310 new cancer cases and an estimated 609,820 cancer deaths in the United States in 2023. As a result, the growing prevalence of cancer is expected to propel the demand for in vitro diagnostics.
Major players in the in vitro diagnostics (IVD) market are incorporating advanced technologies, such as UIMG image technology and 2D decoder chips, to enhance diagnostic accuracy and efficiency, improve data analysis, optimize workflows, and ultimately deliver better patient outcomes. UIMG image technology is an advanced imaging technique used in diagnostics to capture and analyze high-resolution images, enhancing the visualization and interpretation of biological samples. For example, in November 2023, Newland, a Netherlands-based technology company in the EMEA region, launched a new IVD product line. This product line includes five barcode scanners that are compact, durable, and designed to optimize automated diagnostic processes, aiming to boost diagnostic speed and accuracy in response to the growing demand for efficient healthcare solutions.
In June 2025, bioMerieux, a France-based provider of in vitro diagnostics solutions, acquired Day Zero Diagnostics for approximately $25 million. This acquisition strengthens bioMerieux's next-generation sequencing (NGS) capabilities and enhances its rapid diagnostics portfolio, allowing the company to better address antibiotic-resistant infections and improve the management of life-threatening infectious diseases. Day Zero Diagnostics, a US-based company, specializes in genome sequencing and machine learning technologies that enable the rapid identification of bacterial pathogens and their antibiotic resistance profiles directly from whole blood samples
Major companies operating in the in vitro diagnostics market are Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., bioMerieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Crop., Natera Inc., Invitae Crop., Veracyte Inc.
North America was the largest region in the global in-vitro diagnostics market in 2025. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the in vitro diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
In Vitro Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses in vitro diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for in vitro diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in vitro diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.